WS01.4 VX-661 in combination with ivacaftor in patients with cystic fibrosis and the F508del-CFTR mutation

  • Pilewski J
  • Cooke J
  • Lekstrom-Himes J
  • et al.
Citations of this article
Mendeley users who have this article in their library.


BACKGROUND The F508del and G551D mutations affect CFTR in different ways. VX-661 increases the quantity of functional F508del-CFTR at the cell surface, and ivacaftor (IVA) increases CFTR gating; effects are additive in vitro. METHODS This randomized, double-blind, placebo-controlled, multi-cohort, phase 2 study evaluated escalating doses of VX-661 alone and in combination with IVA (150 mg q12h) in F508del/F508del patients, or the addition of VX-661 (100 mg qd) to F508del/G551D patients on prescribed IVA. Primary outcomes were safety and change in sweat chloride through Day 28. Percent predicted FEV1 (ppFEV1) was a secondary endpoint. RESULTS The reported cohorts included 128 patients homozygous for F508del and 18 with F508del/G551D. In patients homozygous for F508del, at Day 28, VX-661 monotherapy resulted in reductions in sweat chloride but non-significant increases in ppFEV1, whereas VX-661/IVA decreased sweat chloride 5.7 mmol/L (P<0.05 within group; n = 14) and increased ppFEV1 4.8 absolute points (P = 0.01 vs placebo; n = 15). In F508del/G551D patients, through Day 28, VX-661/IVA led to a mean reduction in sweat chloride of 7.0 mmol/L (P = 0.053; n = 13) and significant within-group changes in absolute ppFEV1 (4.6 points, P = 0.012; n = 14). The overall incidence of AEs in VX-661/IVA-treated patients was similar across treatment groups and was comparable to placebo; the most common events were pulmonary exacerbation, cough, headache, nausea, and increased sputum. CONCLUSION These data show that the VX-661/IVA combination may benefit patients with CF who are homozygous for F508del and may enhance the benefit of IVA in CF patients with F508del/G551D.




Pilewski, J. M., Cooke, J., Lekstrom-Himes, J., & Donaldson, S. (2015). WS01.4 VX-661 in combination with ivacaftor in patients with cystic fibrosis and the F508del-CFTR mutation. Journal of Cystic Fibrosis, 14, S1.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free